Safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes mellitus in the Pakistani population: Results from the A1chieve study

Journal of the Pakistan Medical Association

Volumn 62, Issue 9, 2012, Pages 929-936

  Hassan, Mohammad Imtiaz ^a   Aamir, Azizul Hasan ^b   Miyan, Zahid ^c   Siddiqui, Laiq Ahmed ^d   Qureshi, Muhammad Saleem ^e   Shaikh, Muhammad Zaman ^f  

^a Diabetic Institute of Pakistan   (Pakistan)

^b Postgraduate Medical Institute   (Pakistan)

^c BMU   (Pakistan)

^d NOVO NORDISK A S   (Denmark)

^e KRL Hospital   (Pakistan)

^f DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Biphasic insulin aspart 30; Oral antidiabetic drugs; Pakistani population; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN ASPART; INSULIN DETEMIR; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PAKISTAN; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL AVAILABILITY; BIPHASIC INSULINS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; MALE; MIDDLE AGED; PAKISTAN; PHARMACOVIGILANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84865835805     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 Suppl 1: S64-S71.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
3. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
6. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515.
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
8. American diabetes association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 Suppl 1: S33-S50.
9. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
10. IDF Clinical Guidelines Task Force: Global guideline for type 2 diabetes. Brussels, International Diabetes Federation. (Online) (Cited 2012 June 29). Available from URL: http://wwwidforg 2005.
11. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
12. Jang HC, Guler S, Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008; 62: 1013-1018.
13. Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009; 63: 966-972.
14. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non- Western countries: the A1chieve study. Diabetes Res Clin Pract 2011; 94: 352-363.
15. Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 2010; 88 Suppl 1: S11-S16.
16. Elm EV, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med 2007; 4: e296.
17. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM; BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 724-732.
18. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
19. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM; PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008;10: 212-222.
20. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl 1: 1-68.
21. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
22. Ng KW, Allen ML, Desai A, Macrae D, Pathan N. Cardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patients. Circulation 2012; 125: 721-8.
23. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; (6): CD008143.
24. Jacobson AM. Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract 2004; 10: 502-508.
25. Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract 2011; 94: 364-370.
26. Waki N, Memon A, Khan MO, Faruqi H, Masood S, Rauf M, et al. Current understanding of treatment and management protocol for adult diabetic in patients at a tertiary care hospital. J Pak Med Assoc 2012; 62: 520-524.